{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:04:23Z","timestamp":1761807863786},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T00:00:00Z","timestamp":1403136000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2014,6]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Molecular characterisation of non\u2010squamous non\u2010small\u2010cell lung cancer (NSCLC<\/jats:styled-content>) is required to direct optimal treatment. Treatment of NSCLC<\/jats:styled-content> with inhibitors of epidermal growth factor receptor (EGFR<\/jats:styled-content>) tyrosine kinase (EGFR\u2010TKI<\/jats:styled-content>) should be guided by the presence of activating mutations of the EGFR<\/jats:styled-content> gene.<\/jats:p><\/jats:sec>Aim<\/jats:title>To gain insight into the rate of testing, the range of tissues samples, test utility and outcome when cost of testing as a barrier to access is removed in the A<\/jats:styled-content>ustralian setting.<\/jats:p><\/jats:sec>Methods<\/jats:title>In October<\/jats:styled-content> 2010, a sponsored programme was commenced to gather data on EGFR<\/jats:styled-content> gene mutation testing in A<\/jats:styled-content>ustralia. Partnering laboratories were funded for provision of de\u2010identified results. For participating patients, the programme supported the test charge. Mutation testing was performed using S<\/jats:styled-content>anger sequencing of exons 18\u201321 of the EGFR<\/jats:styled-content>.<\/jats:p><\/jats:sec>Results<\/jats:title>Samples 2013 were submitted from 2012 patients. Full sequencing was achieved in 1717 (85%). Failure of full sequencing was more likely in samples derived from fine needle aspiration(FNA<\/jats:styled-content>) biopsy than tissue biopsy or pleural\/pericardial fluid cell blocks OR<\/jats:styled-content> 3.1 (95% CI 1.9\u20135.2). There were 359 mutations seen in 337 patients. 14.5% of cases had a classical mutation conferring sensitivity to EGFR\u2010TKI<\/jats:styled-content>. In addition there was a range of less common mutations \u2013 some predicting responses and others of uncertain significance. 1.4% of cases had mutations associated with non\u2010responsiveness to EGFR\u2010TKI<\/jats:styled-content>.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>EGFR<\/jats:styled-content> gene mutation testing is feasible on local and interstate lung cancer samples. The rate of valid test outcomes is high, but FNA<\/jats:styled-content> samples are associated with more frequent test failure.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.12449","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T18:19:15Z","timestamp":1397153955000},"page":"575-580","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes of an A<\/scp>ustralian testing programme for epidermal growth factor receptor mutations in non\u2010small cell lung cancer"],"prefix":"10.1111","volume":"44","author":[{"given":"M. J.","family":"Peters","sequence":"first","affiliation":[{"name":"Concord Repatriation General Hospital Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Bowden","sequence":"additional","affiliation":[{"name":"Flinders Medical Centre Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Carpenter","sequence":"additional","affiliation":[{"name":"AstraZeneca Pty Ltd Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lewis","sequence":"additional","affiliation":[{"name":"AstraZeneca Pty Ltd Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,6,19]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"Cancer Survival and Prevalence in Australia: Period Estimates from 1982 to 2010","author":"Australian Institute of Health and Welfare","year":"2012"},{"key":"e_1_2_7_3_1","volume-title":"Cancer in Australia: An Overview 2010","author":"Australian Institute of Health and Welfare","year":"2010"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2000.tb124122.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05945"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214886"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70087-6"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1846"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3408"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.6993"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405220101"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8923"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.12.5463"},{"key":"e_1_2_7_15_1","volume-title":"Lung Cancer in Australia: An Overview. Cancer Series no. 64. Cat. no. CAN 58","author":"AIHW and Cancer Australia","year":"2011"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.71"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-1219"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0620"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044238"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1671"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2361"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.12449","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.12449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T10:30:46Z","timestamp":1696156246000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.12449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1111\/imj.12449"],"URL":"https:\/\/doi.org\/10.1111\/imj.12449","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"2014-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}